GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma
Completed · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
Vaccines made from a person's tumor cells, such as gp96 heat shock protein-peptide complex, may help the body build an effective immune response to kill tumor cells. This phase I/II trial is studying the side effects and best dose of gp96 heat shock protein-peptide complex vaccine to see how well it works in treating patients with recurrent or progressive high-grade glioma over time.
Key facts
- Study ID
- NCT00293423
- Run by
- University of California, San Francisco
- People needed
- 96
- Starts
- 2005-11-18
- Expected to finish
- 2013-01-12
- Last updated by the study team
- 2021-05-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, San Francisco — San Francisco, California, United States
- Columbia University — New York, New York, United States
- University Hospitals Case Medical Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.